Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Liver disease
•
Endocrinology
•
Thyroid Disorders
How do you evaluate and manage Rezdiffra (resmetirom)-induced abnormal thyroid function tests?
Related Questions
In which specific scenarios would you consider transitioning from oral to intravenous thyroid hormone replacement in the outpatient setting?
How would you approach levothyroxine dosing in a patient with congenital hypothyroidism who has persistent mid-normal TSH but elevated free T4 levels?
Do you avoid the use of beta blockers when treating hyperthyroidism in patients with well controlled asthma or COPD?
How do you counsel patients with elevated Thyroglobulin Peroxidase antibody levels, diffuse thyroiditis features on ultrasound, non-specific symptoms of fatigue, but normal biochemical thyroid function labs?
How do you assess and adjust treatment in patients who develops hypothyroidism after being on lithium for several years?
Do you recommend low dose RAI ablation for low risk papillary thyroid cancer with lymphatic invasion alone (no angio-invasion or known nodal involvement)?
Are there specific populations with hypothyroidism for whom you would consider adding liothyronine to levothyroxine therapy, given observational data linking levothyroxine therapy alone to higher risks of dementia and mortality?
What doses of methimazole do you consider "low dose" when treating Graves' disease long-term?
Should a different weight-based dosing algorithm for levothyroxine therapy be considered in women versus men given higher incidence of iatrogenic thyrotoxicosis in women?
Do you have a preference between RAI therapy and antithyroid medication for patients with Graves' hyperthyroidism and moderate-to-severe Graves' orbitopathy who are on glucocorticoid treatment?
